Establishing disease-specific thresholds for automated hematopoietic progenitor cell counting in hematological malignancies
PLOS One · 08.10.2025 · 20 (10) · e0333196
DOI: 10.1371/journal.pone.0333196 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 08.10.2025. Verfasst von Orathai Taka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sysmex (Thailand) Co., Ltd..
Abstract (Originalsprache)
Background
Flow cytometry remains the gold-standard method for enumerating CD34 + cells during peripheral blood stem cell (PBSC) transplantation, but it is resource- and time-intensive. This study aimed to assess the correlation between hematopoietic progenitor cell (HPC) counts measured by a Sysmex XN-series analyzer and CD34 + cell counts obtained by flow cytometry in pre-apheresis peripheral blood and apheresis products, and to establish HPC cutoffs for predicting adequate PBSC yields.
Methods
We analyzed 334 samples (167 pre-apheresis peripheral blood, 167 PBSC apheresis products) collected from patients and healthy donors. HPC and CD34 + cell counts were measured in all samples. Receiver operating characteristic (ROC) curve analysis was performed to determine HPC cutoff values predictive of adequate PBSC harvest.
Results
Intraclass correlation coefficients (ICCs) indicated strong HPC‒CD34 + concordance in pre-apheresis peripheral blood (ICC = 0.896, p < 0.001) and apheresis products (ICC = 0.958, p < 0.001). Median HPC counts were significantly higher than CD34 + cell counts overall (16 vs. 14.6/µL, p < 0.001; 1,040 vs. 804.73/µL, p < 0.001). The same trend was observed in multiple myeloma (50 vs. 23.92/µL, p < 0.001; 1,290 vs. 1,132.85/µL, p = 0.002) and lymphoma (7 vs. 2.48/µL, p = 0.011; 615 vs. 475.12/µL, p = 0.004). In healthy donors, median HPC counts in apheresis products also exceeded CD34 + cell counts (1,580 vs. 1,430.45/µL, p = 0.005). The HPC cutoffs predicting peripheral blood CD34+ > 20/µL and a CD34 + cell yield of ≥ 2 × 10 6 cells/kg were 21/µL overall (sensitivity 91.5%, specificity 90.6%), 27/µL for multiple myeloma (87.2%, 81.3%), and 20/µL for lymphoma (83.3%, 95.2%).
Conclusions
This study establishes the first disease-specific HPC cutoff values targeting the clinically critical 2 × 10 6 cells/kg threshold: 27 cells/μL for multiple myeloma and 20 cells/μL for lymphoma. This precision medicine approach advances beyond universal cutoffs, enabling optimized collection timing and potentially reducing healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand.
ORCID-Profile: Weerapat Owattanapanich
Förderung
- Sysmex (Thailand) Co., Ltd.
Zitieren
APA
Taka, O., Thedsawad, A., & Owattanapanich, W. (2025). Establishing disease-specific thresholds for automated hematopoietic progenitor cell counting in hematological malignancies. PLOS One, 20(10), e0333196. https://doi.org/10.1371/journal.pone.0333196
Vancouver
Taka O, Thedsawad A, Owattanapanich W. Establishing disease-specific thresholds for automated hematopoietic progenitor cell counting in hematological malignancies. PLOS One. 2025;20(10):e0333196. doi:10.1371/journal.pone.0333196
BibTeX
@article{Taka2025,
author = {Taka, Orathai and Thedsawad, Anchalee and Owattanapanich, Weerapat},
title = {Establishing disease-specific thresholds for automated hematopoietic progenitor cell counting in hematological malignancies},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0333196},
doi = {10.1371/journal.pone.0333196}
}
EUVIMED